Modular Genetics is a sustainable chemistry company with a patented, automated strain engineering process which enables the modification of various organisms to produce green specialty chemicals via fermentation. Modular is focused on sustainable chemistry and is a leading company in today’s Industrial Biotechnology Revolution.  Modular is positioned to take a leading role as the world transitions from a petroleum-based economy to an economy based on renewable raw materials.

Link

RVC USA / Maxwell Biotech is a visionary and strategic investor of early-stage capital that melds the innovation of U.S. start-ups with the resources of Russia. Whether your focus is information technology, life sciences, semi-conductor or alternative energy/clean technology, we have a strong track record of delivering value beyond capital that ensures your venture is primed and ready for the next phase of growth.

Link

Celexion LLC is a protein discovery and engineering company based in Cambridge, Massachusetts.  We use our proprietary platform to display complex proteins on the surface of eukaryotic cells.  This platform combined with state-of-the-art library construction and screening capabilities, allows us to rapidly discover and engineer new proteins for applications in therapeutics, diagnostics, and life science tools.

Link

Navidea Biopharmaceuticals is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing three radiopharmaceutical agent platforms – Lymphoseek®, AZD4694 and RIGScanTM – to help identify the presence and status of undetected disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts.

Link

Bio-Tree Systems, Inc was formed in mid-2000 under the guidance of Dr. Judah Folkman, the discoverer of tumor angiogenesis. The company is inventing the new life science informatics field of VASCULOMICS(tm). This field is enabling a novel disease diagnostics and therapy personalization based on geometric informatics extracted from micro-vascular trees in the diseased locations. There are over 100 disease classes expressed by abnormal vascular patterns which can be diagnosed and characterized by VASCULOMICS(tm). Our initial disease indication is cancer. In this area we are working major pharmaceuticals in oncology drug discovery where we enable quantification, through micro-vascular geometry informatics and in full 3D, mechanism and efficacy of single compounds and combinations irrespective of inhibition pathway. We are also expanding the reach of VASCULOMICS(tm) to the CNS and Diabetes areas. In diabetes we plan to focus on Nephropathy, Retinopathy and Neuropathy (a.k.a. Peripheral Vascular Disease or PVD). In CNS we are entering the STROKE and Traumatic Brain Injury (TBI) areas, with longer term objective to expand to Neuro-Degenerative Diseases. Currently our work is in the pre-clinical space. We are in process of expanding the reach of the VASCULOMICS(tm) technology to the clinic, with the goal of covering diseases “from the bench to the bedside”.

Link

Patheon is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. The company provides the highest quality products and services to approximately 300 of the world’s leading pharmaceutical and biotechnology companies. Its services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, softgel, solid and liquid forms.  The company’s comprehensive range of fully integrated Pharmaceutical Development Services includes preformulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. The company’s integrated development and manufacturing network of 10 manufacturing facilities, nine development centers and one clinical trial material packaging facility across North America and Europe, enables customer products to be launched with confidence anywhere in the world.

Link